Prevalence and Clinical Significance of Hypercalcemia at Diagnosis in Diffuse Large B Cell Lymphoma

Abadi, Uri; Peled, Lee; Rotman-Pikielny, Pnina; Raanani, Pia; Ellis, Martin; Rozovski, Uri; Gurion, Ronit

doi:10.1002/hon.90_2631

Cited by 2 publications

(4 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…18,19 Association between hypercalcemia and poor prognostic factors such as elevated LDH, low levels of albumin and advanced stage, has been recently reported. 11 We confirmed these data and additionally 21 Finally, we tried to explore association between hypercalcemia and biological data reflecting the heterogeneity of DLBCL.…”

Section: Discussionsupporting

confidence: 52%

“…showed that hypercalcemic patients with low PTH levels (lymphomarelated hypercalcemia) had more adverse characteristics and shorter PFS and OS than patients with normal or elevated PTH levels (PHPTrelated hypercalcemia). 11 To avoid this bias, we excluded all patients with known PHPT and/or with high PTH level. Unfortunately, only one quarter of the patients with hypercalcemia had PTH levels available.…”

Section: Discussionmentioning

confidence: 99%

“…10 Only one recent study has investigated the impact of hypercalcemia specifically in newly diagnosed DLBCL and demonstrated that patients with lymphoma-related hypercalcemia have an adverse prognosis compared to normocalcemic patients. 11 The aims of the present retrospective study, were, first, to investigate the prevalence of hypercalcemia at diagnosis of de novo DLBCL compared to transformed indolent lymphomas and, second, to explore its clinical significance and prognostic value in de novo DLBCL.…”

mentioning

confidence: 99%

See 2 more Smart Citations

Hypercalcemia at diagnosis of diffuse large B‐cell lymphoma is not uncommon and is associated with high‐risk features and a short diagnosis‐to‐treatment interval

Gauchy

Kanagaratnam

Quinquenel

et al. 2020

Hematological Oncology

View full text Add to dashboard Cite

Diffuse large B-cell lymphoma (DLBCL) is an aggressive type of non-Hodgkin lymphoma. The prevalence of hypercalcemia in this neoplasm and its prognostic significance is unclear. We retrospectively evaluated the prevalence of hypercalcemia at diagnosis of DLBCL and explored associations of hypercalcemia with clinical factors and outcome. Outcome was assessed using event-free survival at 24 months (EFS24). A total of 305 patients (248 de novo DLBCL and 57 transformed indolent lymphomas) diagnosed between 2006 and 2018 in Reims were analyzed. The prevalence of calcemia >10.5 mg/dL at diagnosis of de novo DLBCL and transformed indolent lymphomas was 23% and 26%, respectively. Hypercalcemia in de novo DLBCL was strongly associated with high-risk features, especially with International Prognostic Index (IPI) components, but also with B symptoms, β2-microglobulin, hemoglobin, and albumin levels. The diagnosis-to-treatment interval was significantly shorter for hypercalcemic patients (P = .001). These associations with adverse prognostic factors translated into lower rates of EFS24 (HR = 1.66; 95% CI, 1.08-2.54) and shorter PFS (P = .0059) and OS (P = .0003) for patients with lymphoma-related hypercalcemia but not independently of IPI parameters. These data suggest that hypercalcemia is rather a biomarker of the underlying biological aggressiveness of DLBCL.

show abstract

Section: Discussionsupporting

confidence: 52%

Section: Discussionmentioning

confidence: 99%

mentioning

confidence: 99%

See 1 more Smart Citation

Hypercalcemia at diagnosis of diffuse large B‐cell lymphoma is not uncommon and is associated with high‐risk features and a short diagnosis‐to‐treatment interval

Gauchy

Kanagaratnam

Quinquenel

et al. 2020

Hematological Oncology

View full text Add to dashboard Cite

show abstract

“…Well-recognized prognostic factors for DLBCL include age, performance status, LDH, Ann Arbor stages, and a number of affected extranodal sites, which are incorporated into IPI, the most popular system used to predict prognosis [35]. Other prognostic factors include gender, serum β 2 -MG, tumor bulk, and B symptoms.…”

Section: Discussionmentioning

confidence: 99%

Immunoglobulin D (IgD) and IgD receptor expression in diffuse large B-cell lymphoma

Dai

Jia

et al. 2019

Hematology

View full text Add to dashboard Cite

Objective: Immunoglobulin D (IgD) levels are often elevated in patients with autoimmune diseases. However, the oncogenic activities of IgD and IgD receptor (IgDR) in diffuse large Bcell lymphoma (DLBCL) have not been reported in detail. Therefore, we aimed to investigate the expression of IgD and IgDR in patients with DLBCL. Methods: Membrane IgD (mIgD) and IgDR expression in tissue samples was analyzed using IHC, mIgD and IgDR expression on peripheral blood mononuclear cells (PBMCs) was analyzed by FCM, and secreted IgD (sIgD) level was analyzed by ELISA. Fisher's exact test and Spearman correlation analysis were used to evaluate the relationship between IgD, IgDR, and clinical parameters. Results: The pathological lymph nodes of 34 patients with DLBCL were studied, and mIgD and IgDR expression was found in 16 and 19 patients. mIgD and IgDR expression was upregulated in patients with DLBCL and mIgD expression was significantly associated with IgDR expression. Further correlation analysis showed that mIgD expression was correlated with serum β 2-MG level and Hans algorithm as germinal center B (GCB), whereas IgDR expression correlated with serum LDH level, IPI score and GCB. ELISA showed that sIgD level was significantly increased in DLBCL patients and it correlated with serum β 2-MG and LDH levels. FCM showed that mIgD and IgDR expression in PBMCs of patients with DLBCL was significantly higher than that in healthy controls. Conclusion: Our findings suggest that overexpression of IgD and IgDR is an abnormal activation state in DLBCL.

show abstract

Prevalence and Clinical Significance of Hypercalcemia at Diagnosis in Diffuse Large B Cell Lymphoma

Cited by 2 publications

References 0 publications

Hypercalcemia at diagnosis of diffuse large B‐cell lymphoma is not uncommon and is associated with high‐risk features and a short diagnosis‐to‐treatment interval

Hypercalcemia at diagnosis of diffuse large B‐cell lymphoma is not uncommon and is associated with high‐risk features and a short diagnosis‐to‐treatment interval

Immunoglobulin D (IgD) and IgD receptor expression in diffuse large B-cell lymphoma

Contact Info

Product

Resources

About